Mark Brosius 10b5-1 trades at ISRG (NASDAQ: ISRG) include $2.46M sale
Rhea-AI Filing Summary
Mark Brosius reported sales of ISRG common stock under 10b5-1 plans. The filing lists multiple 10b5-1 sales including
The filing also lists securities to be sold as Performance Stock Units (522,
Positive
- None.
Negative
- None.
Insights
Routine 10b5-1 sales by Mark Brosius; several trades across Dec 2025–Mar 2026.
The filing lists multiple 10b5-1 sales executed by Mark Brosius with discrete trade dates and per-trade proceeds, for example
Such filings document reported dispositions rather than changing company fundamentals; cash-flow treatment and any issuer involvement are not detailed in the excerpt. Subsequent SEC filings or trading disclosures would show further activity if additional 10b5-1 trades occur.
FAQ
What did Mark Brosius report in the ISRG Form 144?
How many shares and proceeds are shown for the largest trade?
Does the filing show planned awards or other securities to be sold?
Are these sales labeled as 10b5-1 plan transactions?